全文获取类型
收费全文 | 104740篇 |
免费 | 8845篇 |
国内免费 | 1997篇 |
专业分类
耳鼻咽喉 | 1148篇 |
儿科学 | 2769篇 |
妇产科学 | 3037篇 |
基础医学 | 4399篇 |
口腔科学 | 4866篇 |
临床医学 | 9894篇 |
内科学 | 12380篇 |
皮肤病学 | 1795篇 |
神经病学 | 7344篇 |
特种医学 | 2351篇 |
外国民族医学 | 25篇 |
外科学 | 13587篇 |
综合类 | 16882篇 |
现状与发展 | 8篇 |
一般理论 | 5篇 |
预防医学 | 7557篇 |
眼科学 | 1840篇 |
药学 | 9607篇 |
172篇 | |
中国医学 | 9017篇 |
肿瘤学 | 6899篇 |
出版年
2024年 | 110篇 |
2023年 | 1816篇 |
2022年 | 2492篇 |
2021年 | 4342篇 |
2020年 | 4837篇 |
2019年 | 4023篇 |
2018年 | 3776篇 |
2017年 | 3981篇 |
2016年 | 4217篇 |
2015年 | 3858篇 |
2014年 | 7612篇 |
2013年 | 9933篇 |
2012年 | 6975篇 |
2011年 | 7285篇 |
2010年 | 6112篇 |
2009年 | 5401篇 |
2008年 | 4866篇 |
2007年 | 4982篇 |
2006年 | 4481篇 |
2005年 | 3805篇 |
2004年 | 3194篇 |
2003年 | 2752篇 |
2002年 | 2302篇 |
2001年 | 1897篇 |
2000年 | 1567篇 |
1999年 | 1211篇 |
1998年 | 949篇 |
1997年 | 796篇 |
1996年 | 716篇 |
1995年 | 650篇 |
1994年 | 590篇 |
1993年 | 517篇 |
1992年 | 419篇 |
1991年 | 395篇 |
1990年 | 268篇 |
1989年 | 294篇 |
1988年 | 246篇 |
1987年 | 225篇 |
1986年 | 214篇 |
1985年 | 266篇 |
1984年 | 215篇 |
1983年 | 143篇 |
1982年 | 179篇 |
1981年 | 140篇 |
1980年 | 124篇 |
1979年 | 118篇 |
1978年 | 64篇 |
1977年 | 60篇 |
1976年 | 52篇 |
1975年 | 28篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):634-644.e5
BackgroundProsthetic choice for mitral valve replacement is generally driven by patient age and patient and surgeon preference, and current guidelines do not discriminate between different etiologies of mitral valve disease. Our objective was to assess and compare short- and long-term outcomes after mitral valve replacement among patients with biological or mechanical prostheses in the setting of severe ischemic mitral regurgitation.MethodsBetween 2000 and 2016, 424 patients underwent mitral valve replacement for severe ischemic mitral regurgitation at our institution, using biological prosthesis in 188 (44%) and mechanical prosthesis in 236 (56%). A 1:1 propensity score match (n = 126 per group) and inverse probability of treatment weighting were used to compare groups. Short-term outcomes included in-hospital mortality and other cardiovascular adverse events. Long-term outcomes included survival and hospital readmission for cardiovascular causes, stroke, and major bleeding.ResultsIn-hospital mortality and early postoperative adverse events were similar between groups in the propensity score match and inverse probability of treatment weighting cohorts. Overall long-term survival was similar at 5 and 9 years, but mechanical prosthesis recipients were more frequently readmitted to hospital for cardiovascular causes, including stroke and non-neurological bleeding in propensity score matching and inverse probability of treatment weighting analyses (all P values < .004). Type of prosthesis did not independently influence all-cause mortality (hazard ratio, 1.01; 95% confidence interval, 0.71-1.43; P = .959), but placement of a mechanical prosthesis was associated with increased risk of readmission for cardiovascular events (hazard ratio, 1.65; 95% confidence interval, 1.17-2.32; P = .004) among matched patients.ConclusionsThe type of prosthesis has no influence on long-term survival among patients with severe ischemic mitral regurgitation undergoing mitral valve replacement. There may be an increased risk of neurologic events and serious bleeding associated with mechanical prostheses. 相似文献
42.
43.
目的 探讨滋肾育胎丸加减方预防抗磷脂抗体(ACA)阳性者不良妊娠结局的效果及机制研究。方法 选取2016年2月至2019年2月我院收治的89例ACA阳性,先兆性流产或有习惯性流产(RSA)史患者,将采用西医治疗的40例作为对照组,将采用西医联合滋肾育胎丸加减方治疗的49例作为观察组,比较两组中医证候疗效、中医证候积分、ACA-IgA、ACA-IgM、ACA-IgG、凝血指标[血小板聚集功能(PAF)、活化蛋白C(PC)、抗凝血酶(AT)、纤溶酶原激活抑制物-1(PAI-1)]、Th1/Th2细胞因子[干扰素γ(IFN-γ)、白介素-2(IL-2)、白介素-4(IL-4)、白介素-10(IL-10)]、妊娠结局、安全性。结果 治疗2周后检测ACA,观察组2例未降低,对照组11例未降低,观察组未降低患者占比低于对照组(P<0.05);观察组总有效率100.00%高于对照组85.00%(P<0.05);观察组治疗4周、7周后中医证候积分低于对照组(P<0.05);观察组治疗4周、7周后ACA-IgA、ACA-IgM、ACA-IgG低于对照组(P<0.05);观察组治疗4周、7周后PAF、PAI-1低于对照组,PC、AT高于对照组(P<0.05);观察组治疗4周、7周后IFN-γ、IL-2低于对照组,IL-4、IL-10高于对照组(P<0.05);观察组活产率95.92%高于对照组80.00%(P<0.05);组间不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 动态监测ACA对滋肾育胎丸加减方精准应用具有指导意义,指导滋肾育胎丸加减方通过调理脏腑、气血、经络功能,改善先兆性流产或有RSA史患者临床症状及凝血因子指标,降低ACA水平,并可改善患者免疫耐受功能,提高胎儿活产率,且安全性高。 相似文献
44.
目的 分析不同特征的结直肠癌患者就医行为选择在中医院(含中西医结合医院)、西医院及肿瘤专科医院间的差异,为合理引导结直肠癌患者适宜就医及制订相关政策提供依据。方法 收集北京地区2018年1月-2019年12月17家三级甲等医院21894例首诊结直肠癌成年住院患者的病案首页数据,采用EmpowerStats 2.0对数据进行描述性分析。结果 21894例结直肠癌患者中就诊于中医院的有862例(3.93%),西医院的有8723例(39.85%),肿瘤专科医院的有12309例(56.22%)。对于不同医疗机构,男性占比均大于女性,58-68岁患者占比最大。且结直肠癌患者年龄、医疗付款方式及肿瘤分期在不同医疗机构间的分布存在差异(P<0.001)。西医院及肿瘤专科医院结直肠癌Ⅲ期患者占比最大,而就诊于中医院患者中结直肠癌Ⅳ期最多。从地域分布来看,异地就诊比例(57.32%)大于本地,且就诊于肿瘤专科医院的患者中73.66%来自外地。患者来源前三名分别是北京市、河北省及内蒙古自治区。而在北京市内,西医院患者主要来源于朝阳区、海淀区及西城区,中医院患者主要来源于海淀区、朝阳区及丰台区,肿瘤专科医院则主要来源于朝阳区、海淀区及丰台区。结论 应大力倡导年轻以及早期结直肠癌患者向中医院分流,充分施展中医药在结直肠癌患者中的治疗优势;发挥三级医院带动作用,建立对口帮扶医院,减少不必要的跨省流动及提倡结直肠癌的早筛早治,以降低结直肠癌死亡率。 相似文献
45.
46.
BackgroundAnterior cruciate ligament (ACL) reconstruction is recommended in patients who intend to return to high-level sports. However, there is only a 55–80% return to pre-injury level of sports after ACL reconstruction, with a re-injury rate up to 20%. The aim of this study was to determine the percentage of patients passing the Back in Action (BIA) test 9 months after primary bone-patellar-tendon-bone (BPTB) ACL reconstruction, and evaluate the association between passing the BIA test and patient reported outcome measurements (PROMs).MethodsPatients underwent the BIA test 9 months after BPTB ACL reconstruction. In total 103 patients were included. Passing the BIA test (PASSED-group) was defined as a normal or higher score at all sub-tests with limb symmetry index (LSI) ≥90% for the dominant leg and LSI >80% for the non-dominant leg. Patients who did not meet these criteria were defined as the FAILED-group. PROMs included the International Knee Documentation Committee, Knee injury Osteoarthritis Outcome Score and Anterior Cruciate Ligament-Return to Sport after Injury.ResultsEighteen patients (17.5%) passed the BIA test 9 months after BPTB ACL reconstruction. PROMs were not statistically significant different between the PASSED- and FAILED-group.ConclusionLow percentage of patients passed the BIA test 9 months after BPTB ACL reconstruction. Although current PROMs cut-off values were met, the BIA test results show persistent functional deficits. Therefore, the BIA test could be of additional value in the decision-making process regarding return to sport (RTS). This study highlights the need for additional rehabilitation as RTS in a condition of incomplete recovery may increase the risk of re-injury.Level of evidenceII. 相似文献
47.
48.
《Patient education and counseling》2022,105(10):3110-3115
IntroductionThe Knowledge of Genome Sequencing (KOGS) questionnaire was recently developed to measure knowledge of genomic sequencing (GS), with preliminary psychometric data supporting its reliability and validity. The aim of this study was to test the reliability and validity of the KOGS in a larger sample, and to confirm its utility in a cancer setting.MethodsThe Genetic Cancer Risk in the Young (RisC) study recruits participants with a personal history of cancer, to investigate heritable cancer causes and future cancer risk using germline GS. Participants (n = 261) in a psychosocial substudy of RisC completed a questionnaire after consent to RisC but before GS, including the KOGS, the Intolerance of Uncertainty Scale, the Chew health literacy scale and items assessing demographic and disease variables. Confirmatory factor analysis (CFA), Cronbach alpha and correlational analyses were undertaken.ResultsThe CFA testing a single-factor model yielded a good model fit, χ2/df = 2.43, comparative fit index (CFI) = 0.97, root mean square error of approximation (RMSEA) = 0.07 and weighted mean root square (WRMR) = 1.03. Factor loadings of all items were above 0.60 and ranged between.66 and.93. The single factor score demonstrated excellent internal consistency (α = 0.82). KOGS scores were significantly associated with health literacy (r = 0.23, p < .001), having a university education [t(258) = ?4.53, p < .001] and having a medical or science background [t(259) = ?3.52, p < .001] but not with speaking a language other than English at home, time since diagnosis, previous genetic counselling/testing or intolerance of uncertainty.DiscussionThis study confirmed a single-factor structure for the KOGS, and its reliability and validity in a cancer population. Associations with measures of health literacy and education were significant and positive as expected, supporting the KOG’s construct validity. Previous genetic counselling may not be sufficient to provide specific knowledge of GS. 相似文献
49.
周纪荣 《中外女性健康研究》2022,(3)
目的对妊娠高血压综合征患者采用个性化健康教育的效果进行探究。方法选择本院收治的妊娠高血压综合征患者84例作为本次研究的纳入对象,时间为2019年4月至2020年4月。按照随机处理的方式对其予以分组,其中甲组42例,乙组42例。通过常规护理的方式对甲组予以护理,以此为基础,通过个性化健康教育的方式对乙组予以护理。比较两组的护理效果。结果护理前,两组的血压水平比较差异不显著(P>0.05),护理后,乙组的血压水平明显低于甲组(P<0.05);乙组的不良妊娠结局率明显低于甲组(P<0.05)。结论针对妊娠高血压综合征患者实施个性化健康教育具有显著效果,能够有效降低患者的血压水平,还可以改善其妊娠结局。 相似文献
50.
Andrea Ferrari MD Daniel Orbach MD Michela Casanova MD Max M. van Noesel MD Pablo Berlanga MD Bernadette Brennan MD Nadege Corradini MD Reineke A. Schoot MD Gema L. Ramirez-Villar MD Lisa Lyngsie Hjalgrim MD Rita Alaggio MD Gabriela Guillen Burrieza MD Akmal Safwat MD Alison L. Cameron MD Rick R. van Rijn MD Veronique Minard-Colin MD Ilaria Zanetti BSc Gianni Bisogno MD Julia C. Chisholm MD Johannes H. M. Merks MD 《Cancer》2023,129(16):2542-2552
Background
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.Methods
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.Results
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2–111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.Conclusions
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.Plain Language Summary
- Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.
- Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.
- This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.